Antioxidants in Cardiovascular Therapy: Panacea or False Hope?

Frontiers in Cardiovascular Medicine

Volumn 2, Issue , 2015, Pages

  Goszcz, Katarzyna ^a,b   Deakin, Sherine J ^a   Duthie, Garry G ^c   Stewart, Derek ^b,d   Leslie, Stephen J ^a,e   Megson, Ian L ^a  

^a UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^b SCOTTISH CROP RESEARCH INSTITUTE   (United Kingdom)

^c ROWETT RESEARCH INSTITUTE   (United Kingdom)

^d HERIOT WATT UNIVERSITY   (United Kingdom)

^e RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

allopurinol; antioxidants; carotenoids; N acetylcysteine; polyphenols; vascular disease; vitamin C; vitamin E

Indexed keywords

EID: 84963883681     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2015.00029     Document Type: Review

References (252)

1. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol (1956) 11(3):298–300.10.1093/geronj/11.3.298
2. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal (2006) 8(9–10):1775–89.10.1089/ars.2006.8.174516987031
3. Yang Y, Bazhin AV, Werner J, Karakhanova S. Reactive oxygen species in the immune system. Int Rev Immunol (2013) 32(3):249–70.10.3109/08830185.2012.75517623617726
4. Shaw A, Doherty MK, Mutch NJ, MacRury SM, Megson IL. Endothelial cell oxidative stress in diabetes: a key driver of cardiovascular complications? Biochem Soc Trans (2014) 42(4):928–33.10.1042/BST2014011325109981
5. Dai DF, Rabinovitch PS, Ungvari Z. Mitochondria and cardiovascular aging. Circ Res (2012) 110(8):1109–24.10.1161/CIRCRESAHA.111.246140
6. Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol Med (2011) 51(2):327–36.10.1016/j.freeradbiomed.2011.05.01021619928
7. van Duynhoven J, Vaughan EE, van Dorsten F, Gomez-Roldan V, de Vos R, Vervoort J, et al. Interactions of black tea polyphenols with human gut microbiota: implications for gut and cardiovascular health. Am J Clin Nutr (2013) 98(6 Suppl):1631S–41S.10.3945/ajcn.113.05826324172295
8. Russell WR, Scobbie L, Labat A, Duthie GG. Selective bio-availability of phenolic acids from Scottish strawberries. Mol Nutr Food Res (2009) 53(Suppl 1):S85–91.10.1002/mnfr.20080030219205002
9. Dauchet L, Ferrieres J, Arveiler D, Yarnell JW, Gey F, Ducimetiere P, et al. Frequency of fruit and vegetable consumption and coronary heart disease in France and Northern Ireland: the PRIME study. Br J Nutr (2004) 92(6):963–72.10.1079/BJN2004128615613259
10. Liu S, Manson JE, Lee IM, Cole SR, Hennekens CH, Willett WC, et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women’s Health Study. Am J Clin Nutr (2000) 72(4):922–8.
11. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol (1997) 26(1):1–13.10.1093/ije/26.1.19126498
12. Todd S, Woodward M, Tunstall-Pedoe H, Bolton-Smith C. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish heart health study. Am J Epidemiol (1999) 150(10):1073–80.10.1093/oxfordjournals.aje.a00993110568622
13. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med (1997) 336(16):1117–24.10.1056/NEJM1997041733616019099655
14. Le Brocq M, Leslie SJ, Milliken P, Megson IL. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal (2008) 10(9):1631–74.10.1089/ars.2007.201318598143
15. Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, Abdalla DS. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis (1995) 117(1):61–71.10.1016/0021-9150(94)05558-Z
16. Biswas SK, de Faria JB. Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res (2007) 41(2):216–24.10.1080/1071576060105967217364948
17. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res (2006) 71(2):247–58.10.1016/j.cardiores.2006.05.001
18. West IC. Radicals and oxidative stress in diabetes. Diabet Med (2000) 17(3):171–80.10.1046/j.1464-5491.2000.00259.x
19. Bakker SJ, RG IJ, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis (2000) 148(1):17–21.10.1016/S0021-9150(99)00329-910580166
20. Chalmers A. Smoking and oxidative stress. Am J Clin Nutr (1999) 69(3):572.
21. Megson IL, Haw SJ, Newby DE, Pell JP. Association between exposure to environmental tobacco smoke and biomarkers of oxidative stress among patients hospitalised with acute myocardial infarction. PLoS One (2013) 8(12):e81209.10.1371/journal.pone.008120924339911
22. Bernhard D, Wang XL. Smoking, oxidative stress and cardiovascular diseases – do anti-oxidative therapies fail? Curr Med Chem (2007) 14(16):1703–12.10.2174/09298670778105895917627508
23. Miller MR, Borthwick SJ, Shaw CA, McLean SG, McClure D, Mills NL, et al. Direct impairment of vascular function by diesel exhaust particulate through reduced bioavailability of endothelium-derived nitric oxide induced by superoxide free radicals. Environ Health Perspect (2009) 117(4):611–6.10.1289/ehp.080023519440501
24. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J (2015) 36(2):83–93.10.1093/eurheartj/ehu458
25. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans (2007) 35(Pt 5):1147–50.10.1042/BST0351147
26. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res (2000) 87(10):840–4.10.1161/01.RES.87.10.84011073878
27. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood (1998) 91(10):3527–61.
28. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 320(6061):454–6.10.1038/320454a03007998
29. Hayashi Y, Sawa Y, Nishimura M, Fukuyama N, Ichikawa H, Ohtake S, et al. Peroxynitrite, a product between nitric oxide and superoxide anion, plays a cytotoxic role in the development of post-bypass systemic inflammatory response. Eur J Cardiothorac Surg (2004) 26(2):276–80.10.1016/j.ejcts.2004.03.03315296883
30. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys (1991) 288(2):481–7.10.1016/0003-9861(91)90224-71654835
31. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem (1991) 266(7):4244–50.1847917
32. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxynonenal. Oxid Med Cell Longev (2014) 2014:360438.10.1155/2014/36043824999379
33. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol (2013) 10(4):219–30.10.1038/nrcardio.2013.823380975
34. Lankin VZ, Lisina MO, Arzamastseva NE, Konovalova GG, Nedosugova LV, Kaminnyi AI, et al. Oxidative stress in atherosclerosis and diabetes. Bull Exp Biol Med (2005) 140(1):41–3.10.1007/s10517-005-0406-z
35. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation (2002) 106(11):1390–6.10.1161/01.CIR.0000028465.52694.9B12221058
36. Alexander RW. Theodore cooper memorial lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension (1995) 25(2):155–61.10.1161/01.HYP.25.2.1557843763
37. Libby P. Inflammation in atherosclerosis. Nature (2002) 420(6917):868–74.10.1038/nature01323
38. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med (1999) 340(2):115–26.10.1056/NEJM199901143400207
39. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med (1999) 37(8):777–87.10.1515/CCLM.1999.11810536926
40. Newby DE. Triggering of acute myocardial infarction: beyond the vulnerable plaque. Heart (2010) 96(15):1247–51.10.1136/hrt.2009.175141
41. Biswas SK, Newby DE, Rahman I, Megson IL. Depressed glutathione synthesis precedes oxidative stress and atherogenesis in Apo-E(-/-) mice. Biochem Biophys Res Commun (2005) 338(3):1368–73.10.1016/j.bbrc.2005.10.09816263083
42. Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid Redox Signal (2005) 7(1–2):42–59.10.1089/ars.2005.7.115650395
43. Martinez-Cayuela M. Oxygen free radicals and human disease. Biochimie (1995) 77(3):147–61.10.1016/0300-9084(96)88119-3
44. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods (2002) 265(1–2):49–72.10.1016/S0022-1759(02)00070-4
45. Profumo E, Buttari B, Saso L, Rigano R. Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr Top Med Chem (2014) 14(22):2542–51.10.2174/156802661466614120313032425478882
46. Moon GJ, Kim SJ, Cho YH, Ryoo S, Bang OY. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol (2014) 10(2):140–7.10.3988/jcn.2014.10.2.14024829600
47. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis (2004) 173(1):1–12.10.1016/S0021-9150(03)00239-915177118
48. von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest (1985) 76(4):1626–31.10.1172/JCI1121472997286
49. Anderson EJ, Thayne KA, Harris M, Shaikh SR, Darden TM, Lark DS, et al. Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARgamma activation? Antioxid Redox Signal (2014) 21(8):1156–63.10.1089/ars.2014.588824597798
50. Hajianfar H, Paknahad Z, Bahonar A. The effect of omega-3 supplements on antioxidant capacity in patients with type 2 diabetes. Int J Prev Med (2013) 4(Suppl 2):S234–8.23776730
51. Linseisen J, Hoffmann J, Lienhard S, Jauch KW, Wolfram G. Antioxidant status of surgical patients receiving TPN with an omega-3-fatty acid-containing lipid emulsion supplemented with alpha-tocopherol. Clin Nutr (2000) 19(3):177–84.10.1054/clnu.1999.009610895108
52. Gilbert K, Bernier J, Godbout R, Rousseau G. Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression. Mar Drugs (2014) 12(11):5396–407.10.3390/md1211539625402828
53. Kim TH, Kim GD, Jin YH, Park YS, Park CS. Omega-3 fatty acid-derived mediator, resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol (2012) 14(4):384–91.10.1016/j.intimp.2012.08.00522951188
54. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat (2009) 89(3–4):126–30.10.1016/j.prostaglandins.2009.03.00219737659
55. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 201(5):713–22.10.1084/jem.2004203115753205
56. Watkins ML, Erickson JD, Thun MJ, Mulinare J, Heath CW, Jr. Multivitamin use and mortality in a large prospective study. Am J Epidemiol (2000) 152(2):149–62.10.1093/aje/152.2.14910909952
57. Holmquist C, Larsson S, Wolk A, de Faire U. Multivitamin supplements are inversely associated with risk of myocardial infarction in men and women – Stockholm heart epidemiology program (SHEEP). J Nutr (2003) 133(8):2650–4.12888653
58. Muntwyler J, Hennekens CH, Manson JE, Buring JE, Gaziano JM. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch Intern Med (2002) 162(13):1472–6.10.1001/archinte.162.13.147212090883
59. Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al. Multivitamin use and risk of cancer and cardiovascular disease in the women’s health initiative cohorts. Arch Intern Med (2009) 169(3):294–304.10.1001/archinternmed.2008.54019204221
60. Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. Am J Epidemiol (2011) 173(8):906–14.10.1093/aje/kwq44721343248
61. Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, et al. Multivitamins in the prevention of cardiovascular disease in men: the physicians’ health study II randomized controlled trial. JAMA (2012) 308(17):1751–60.10.1001/jama.2012.14805
62. Moyer VA. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. preventive services task force recommendation statement. Ann Intern Med (2014) 160(8):558–64.10.7326/M14-019824566474
63. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2012) 3:CD007176.10.1002/14651858.CD007470.pub2
64. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr (2003) 22(1):18–35.10.1080/07315724.2003.1071927212569111
65. Nishikimi M, Fukuyama R, Minoshima S, Shimizu N, Yagi K. Cloning and chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. J Biol Chem (1994) 269(18):13685–8.8175804
66. Griffiths HR, Lunec J. Ascorbic acid in the 21st century – more than a simple antioxidant. Environ Toxicol Pharmacol (2001) 10(4):173–82.10.1016/S1382-6689(01)00081-321782574
67. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. J Lipid Res (1992) 33(3):385–97.1314881
68. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A (1996) 93(8):3704–9.10.1073/pnas.93.8.37048623000
69. Levine M, Rumsey SC, Wang Y, Park J, Kwon O, Amano N. In situ kinetics: an approach to recommended intake of vitamin C. Methods Enzymol (1997) 281:425–37.
70. Tsukaguchi H, Tokui T, Mackenzie B, Berger UV, Chen XZ, Wang Y, et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature (1999) 399(6731):70–5.10.1038/1998610331392
71. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature (1993) 364(6432):79–82.10.1038/364079a08316303
72. Duarte TL, Lunec J. Part of the series: from dietary antioxidants to regulators in cellular signalling and gene expression – review: when is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic Res (2005) 39(7):671–86.10.1080/1071576050010402516390819
73. Lehr HA, Frei B, Arfors KE. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci U S A (1994) 91(16):7688–92.10.1073/pnas.91.16.76887519784
74. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr (1991) 54(6 Suppl): 1113S–8S.1962556
75. Maeda N, Hagihara H, Nakata Y, Hiller S, Wilder J, Reddick R. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc Natl Acad Sci U S A (2000) 97(2):841–6.10.1073/pnas.97.2.84110639167
76. Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic acid. Circulation (2002) 105(12):1485–90.10.1161/01.CIR.0000012142.69612.2511914259
77. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr (2006) 83(3):567–74.16522902
78. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation (1997) 96(5):1513–9.10.1161/01.CIR.96.5.15139315540
79. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation (2001) 103(12):1618–23.10.1161/01.CIR.103.12.161811273987
80. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation (1996) 93(6):1107–13.10.1161/01.CIR.93.6.11078653830
81. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem (2001) 276(1):40–7.10.1074/jbc.M00439220011022034
82. Huang A, Vita JA, Venema RC, Keaney JF, Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem (2000) 275(23):17399–406.10.1074/jbc.M002248200
83. Wilkinson IB, Megson IL, MacCallum H, Sogo N, Cockcroft JR, Webb DJ. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol (1999) 34(5):690–3.10.1097/00005344-199911000-0001010547085
84. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Fruit and vegetable intake and population glycosylated haemoglobin levels: the EPIC-Norfolk study. Eur J Clin Nutr (2001) 55(5):342–8.10.1038/sj.ejcn.160116211378807
85. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 346:f10.10.1136/bmj.f1023335472
86. Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ (1995) 310(6994):1563–6.10.1136/bmj.310.6994.15637787644
87. Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res (1993) 34(3):343–58.
88. Traber MG, Sokol RJ, Kohlschutter A, Yokota T, Muller DP, Dufour R, et al. Impaired discrimination between stereoisomers of alpha-tocopherol in patients with familial isolated vitamin E deficiency. J Lipid Res (1993) 34(2):201–10.8429255
89. Schneider C. Chemistry and biology of vitamin E. Mol Nutr Food Res (2005) 49(1):7–30.10.1002/mnfr.200400049
90. Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr (1996) 16:321–47.10.1146/annurev.nu.16.070196.0015418839930
91. Islam KN, Devaraj S, Jialal I. alpha-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation (1998) 98(21):2255–61.10.1161/01.CIR.98.21.22559826311
92. Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest (1996) 98(3):756–63.10.1172/JCI1188488698868
93. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Contessi GB, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med (1997) 22(1–2):117–27.10.1016/S0891-5849(96)00271-78958136
94. Tasinato A, Boscoboinik D, Bartoli GM, Maroni P, Azzi A. d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A (1995) 92(26):12190–4.10.1073/pnas.92.26.121908618868
95. Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev (2001) 6(3):248–71.11410071
96. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb (1993) 13(4):590–600.10.1161/01.ATV.13.4.5908466894
97. Droge W. Free radicals in the physiological control of cell function. Physiol Rev (2002) 82(1):47–95.10.1152/physrev.00018.200111773609
98. Sagach VF, Scrosati M, Fielding J, Rossoni G, Galli C, Visioli F. The water-soluble vitamin E analogue trolox protects against ischaemia/reperfusion damage in vitro and ex vivo. A comparison with vitamin E. Pharmacol Res (2002) 45(6):435–9.10.1006/phrs.2002.099312162942
99. Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with vitamin E administration. Atherosclerosis (2005) 182(2):259–65.10.1016/j.atherosclerosis.2005.02.02416159598
100. Hasty AH, Gruen ML, Terry ES, Surmi BK, Atkinson RD, Gao L, et al. Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model. J Nutr Biochem (2007) 18(2):127–33.10.1016/j.jnutbio.2006.03.01216781857
101. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS). Lancet (1996) 347(9004):781–6.10.1016/S0140-6736(96)90866-18622332
102. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care (2002) 25(11):1919–27.10.2337/diacare.25.11.191912401733
103. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med (2000) 342(3):154–60.10.1056/NEJM20000120342030210639540
104. Jandak J, Steiner M, Richardson PD. Alpha-tocopherol, an effective inhibitor of platelet adhesion. Blood (1989) 73(1):141–9.2910355
105. Norum KR, Blomhoff R. McCollum award lecture, 1992: vitamin A absorption, transport, cellular uptake, and storage. Am J Clin Nutr (1992) 56(4):735–44.1414975
106. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys (1989) 274(2):532–8.10.1016/0003-9861(89)90467-02802626
107. Mayne ST, Cartmel B, Silva F, Kim CS, Fallon BG, Briskin K, et al. Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors. J Nutr (1999) 129(4):849–54.10203560
108. Korytko PJ, Rodvold KA, Crowell JA, Stacewicz-Sapuntzakis M, Diwadkar-Navsariwala V, Bowen PE, et al. Pharmacokinetics and tissue distribution of orally administered lycopene in male dogs. J Nutr (2003) 133(9):2788–92.12949366
109. Dewanto V, Wu X, Adom KK, Liu RH. Thermal processing enhances the nutritional value of tomatoes by increasing total antioxidant capacity. J Agric Food Chem (2002) 50:3010–4.10.1021/jf011558911982434
110. Romanchik JE, Morel DW, Harrison EH. Distributions of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro. J Nutr (1995) 125(10):2610–7.7562097
111. Dugas TR, Morel DW, Harrison EH. Impact of LDL carotenoid and alpha-tocopherol content on LDL oxidation by endothelial cells in culture. J Lipid Res (1998) 39(5):999–1007.9610766
112. Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun (1997) 233(3):658–62.10.1006/bbrc.1997.65209168909
113. Rao AV. Lycopene, tomatoes, and the prevention of coronary heart disease. Exp Biol Med (Maywood) (2002) 227(10):908–13.12424333
114. Grosjean S, Devaux Y, Seguin C, Meistelman C, Zannad F, Mertes PM, et al. Retinoic acid attenuates inducible nitric oxide synthase (NOS2) activation in cultured rat cardiac myocytes and microvascular endothelial cells. J Mol Cell Cardiol (2001) 33(5):933–45.10.1006/jmcc.2001.135611343416
115. Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE. Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the physicians’ health study. Int J Epidemiol (2001) 30(1):130–5.10.1093/ije/30.1.13011171873
116. Hozawa A, Jacobs DR, Jr Steffes MW, Gross MD, Steffen LM, Lee DH. Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the coronary artery risk development in young adults (CARDIA)/young adult longitudinal trends in antioxidants (YALTA) study. Clin Chem (2007) 53(3):447–55.10.1373/clinchem.2006.07493017234732
117. D’Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, Bonvicini P, et al. High plasma levels of alpha- and beta-carotene are associated with a lower risk of atherosclerosis: results from the Bruneck study. Atherosclerosis (2000) 153(1):231–9.10.1016/S0021-9150(00)00403-211058719
118. Watzl B, Kulling SE, Moseneder J, Barth SW, Bub A. A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. Am J Clin Nutr (2005) 82(5):1052–8.16280438
119. Omenn GS, Goodman G, Thornquist M, Barnhart S, Balmes J, Cherniack M, et al. Chemoprevention of lung cancer: the beta-carotene and retinol efficacy trial (CARET) in high-risk smokers and asbestos-exposed workers. IARC Sci Publ (1996) 136:67–85.
120. Kohlmeier L, Kark JD, Gomez-Gracia E, Martin BC, Steck SE, Kardinaal AF, et al. Lycopene and myocardial infarction risk in the EURAMIC Study. Am J Epidemiol (1997) 146(8):618–26.10.1093/oxfordjournals.aje.a0093279345115
121. Karppi J, Laukkanen JA, Makikallio TH, Kurl S. Low serum lycopene and beta-carotene increase risk of acute myocardial infarction in men. Eur J Public Health (2012) 22(6):835–40.10.1093/eurpub/ckr17422158914
122. Muller L, Caris-Veyrat C, Lowe G, Bohm V. Lycopene and its antioxidant role in the prevention of cardiovascular diseases – a critical review. Crit Rev Food Sci Nutr (2015).10.1080/10408398.2013.80182725675359
123. O’Kennedy N, Crosbie L, van Lieshout M, Broom JI, Webb DJ, Duttaroy AK. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. Am J Clin Nutr (2006) 84(3):570–9.16960171
124. O’Kennedy N, Crosbie L, Whelan S, Luther V, Horgan G, Broom JI, et al. Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Am J Clin Nutr (2006) 84(3):561–9.16960170
125. Gajendragadkar PR, Hubsch A, Maki-Petaja KM, Serg M, Wilkinson IB, Cheriyan J. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS One (2014) 9(6):e99070.10.1371/journal.pone.009907024911964
126. Dwyer JH, Navab M, Dwyer KM, Hassan K, Sun P, Shircore A, et al. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation (2001) 103(24):2922–7.10.1161/01.CIR.103.24.292211413081
127. Sesso HD. Carotenoids and cardiovascular disease: what research gaps remain? Curr Opin Lipidol (2006) 17(1):11–6.10.1097/01.mol.0000203888.42514.2716407710
128. Lidebjer C, Leanderson P, Ernerudh J, Jonasson L. Low plasma levels of oxygenated carotenoids in patients with coronary artery disease. Nutr Metab Cardiovasc Dis (2007) 17(6):448–56.10.1016/j.numecd.2006.02.00617134954
129. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ (2004) 11(Suppl 1):S56–64.10.1038/sj.cdd.440145115243582
130. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation (2000) 102(20):2479–83.10.1161/01.CIR.102.20.247911076820
131. Boger RH, Bode-Boger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost (2000) 26(5):539–45.10.1055/s-2000-13210
132. Jiang XH, Yang F, Tan HM, Liao D, Bryan RM, Randhawa JK, et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol (2005) 25(12):2515–21.10.1161/01.ATV.0000189559.87328.e416210565
133. Garcia-Pinilla JM, Espinosa-Caliani S, Gomez-Doblas JJ, Jimenez-Navarro M, Gaitan MJ, Ortega-Jimenez MV, et al. Influence of high homocysteine and low folate plasmatic levels in medium-term prognosis after acute coronary syndromes. Int J Cardiol (2007) 118(2):220–6.10.1016/j.ijcard.2006.06.05317023072
134. Joshi R, Adhikari S, Patro BS, Chattopadhyay S, Mukherjee T. Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity. Free Radic Biol Med (2001) 30(12):1390–9.10.1016/S0891-5849(01)00543-311390184
135. Carnicer R, Navarro MA, Arbones-Mainar JM, Acin S, Guzman MA, Surra JC, et al. Folic acid supplementation delays atherosclerotic lesion development in apoE-deficient mice. Life Sci (2007) 80(7):638–43.10.1016/j.lfs.2006.10.01417118406
136. Endo N, Nishiyama K, Otsuka A, Kanouchi H, Taga M, Oka T. Antioxidant activity of vitamin B6 delays homocysteine-induced atheroscerosis in rats. Br J Nutr (2006) 95(6):1088–93.10.1079/BJN2006176416768830
137. Gao L, Siu K, Chalupsky K, Nguyen A, Chen P, Weintraub NL, et al. Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. Hypertension (2012) 59(1):158–66.10.1161/HYPERTENSIONAHA.111.18164422083158
138. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation (1998) 97(5):437–43.10.1161/01.CIR.97.5.4379490237
139. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin-B12, folate, and vitamin-B6 supplements in elderly people with normal serum vitamin concentrations. Lancet (1995) 346(8967):85–9.10.1016/S0140-6736(95)92113-37603218
140. den Heijer M, Brouwer IA, Bos GMJ, Blom HJ, van der Put NMJ, Spaans AP, et al. Vitamin supplementation reduces blood homocysteine levels – a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol (1998) 18(3):356–61.10.1161/01.ATV.18.3.3569514403
141. Till U, Rohl P, Jentsch A, Till H, Muller A, Bellstedt K, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis (2005) 181(1):131–5.10.1016/j.atherosclerosis.2004.12.04315939064
142. Antoniades C, Shirodaria C, Crabtree M, Ratnatunga C, Pillai R, Neubauer S, et al. Low- and high- dose treatment with folic acid, equally improve endothelial function and decrease superoxide production in human vessels via tetrahydrobiopterin-mediated eNOS coupling. Eur Heart J (2007) 28:741.
143. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death – the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA (2004) 291(5):565–75.10.1001/jama.291.5.56514762035
144. Debreceni B, Debreceni L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther (2012) 30(4):227–33.10.1111/j.1755-5922.2011.00266.x21884001
145. Marti-Carvajal AJ, Sola I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev (2009) 4:CD006612.10.1002/14651858.CD006612.pub2
146. Halliwell B. Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc Res (2007) 73(2):341–7.10.1016/j.cardiores.2006.10.00417141749
147. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr (2004) 79(5):727–47.15113710
148. Watson RR, Preedy VR, Zibadi S. Polyphenols in Health and Disease. London: Academic Press (2014).
149. Stoclet JC, Chataigneau T, Ndiaye M, Oak MH, El Bedoui J, Chataigneau M, et al. Vascular protection by dietary polyphenols. Eur J Pharmacol (2004) 500(1–3):299–313.10.1016/j.ejphar.2004.07.034
150. Quideau S, Deffieux D, Douat-Casassus C, Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl (2011) 50(3):586–621.10.1002/anie.20100004421226137
151. Rodrigo R, Miranda A, Vergara L. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin Chim Acta (2011) 412(5–6):410–24.10.1016/j.cca.2010.11.03421130758
152. Galleano M, Verstraeten SV, Oteiza PI, Fraga CG. Antioxidant actions of flavonoids: thermodynamic and kinetic analysis. Arch Biochem Biophys (2010) 501(1):23–30.10.1016/j.abb.2010.04.00520388486
153. Estevez L, Mosquera RA. Molecular structure and antioxidant properties of delphinidin. J Phys Chem A (2008) 112(42):10614–23.10.1021/jp804323718821739
154. Prochazkova D, Bousova I, Wilhelmova N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia (2011) 82(4):513–23.10.1016/j.fitote.2011.01.018
155. Finley JW, Kong AN, Hintze KJ, Jeffery EH, Ji LL, Lei XG. Antioxidants in foods: state of the science important to the food industry. J Agric Food Chem (2011) 59(13):6837–46.10.1021/jf201387521627162
156. Babich H, Schuck AG, Weisburg JH, Zuckerbraun HL. Research strategies in the study of the pro-oxidant nature of polyphenol nutraceuticals. J Toxicol (2011) 2011:467305.10.1155/2011/46730521776260
157. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys (2008) 476(2):107–12.10.1016/j.abb.2008.01.02818284912
158. Gil-Longo J, Gonzalez-Vazquez C. Vascular pro-oxidant effects secondary to the autoxidation of gallic acid in rat aorta. J Nutr Biochem (2010) 21(4):304–9.10.1016/j.jnutbio.2009.01.00319369049
159. Middleton E, Jr Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev (2000) 52(4):673–751.11121513
160. Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr (2010) 103(10):1398–403.10.1017/S000711450999348520021702
161. Vari R, D’Archivio M, Filesi C, Carotenuto S, Scazzocchio B, Santangelo C, et al. Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-mediated Nrf2 activation in murine macrophages. J Nutr Biochem (2011) 22(5):409–17.10.1016/j.jnutbio.2010.03.00820621462
162. Wallace TC. Anthocyanins in cardiovascular disease. Adv Nutr (2011) 2(1):1–7.10.3945/an.110.000042
163. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem (2011) 22(3):201–11.10.1016/j.jnutbio.2010.07.00421111592
164. Wang S, Melnyk JP, Tsao R, Marcone MF. How natural dietary antioxidants in fruits, vegetables and legumes promote vascular health. Food Res Intern (2011) 44(1):14–22.10.1016/j.foodres.2010.09.028
165. Visioli F, Bernardini E. Extra virgin olive oil’s polyphenols: biological activities. Curr Pharm Des (2011) 17(8):786–804.10.2174/13816121179542888521443485
166. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr (2005) 81(1 Suppl):215S–7S.15640483
167. Kruger MJ, Davies N, Myburgh KH, Lecour S. Proanthocyanidins, anthocyanins and cardiovascular diseases. Food Res International (2014) 59:41–52.10.1016/j.foodres.2014.01.04618209270
168. Li J, Ichikawa T, Janicki JS. Cu8i T. Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets (2009) 13(7):787–94.10.1517/1472822090302576219530984
169. Barbagallo I, Galvano F, Frigiola A, Cappello F, Riccioni G, Murabito P, et al. Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal (2013) 18(5):507–21.10.1089/ars.2011.436023025298
170. Fraga CG, Galleano M, Verstraeten SV, Oteiza PI. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med (2010) 31(6):435–45.10.1016/j.mam.2010.09.00620854840
171. Auger C, Kim JH, Trinh S, Chataigneau T, Popken AM, Schini-Kerth VB. Fruit juice-induced endothelium-dependent relaxations in isolated porcine coronary arteries: evaluation of different fruit juices and purees and optimization of a red fruit juice blend. Food Funct (2011) 2(5):245–50.10.1039/c1fo10040h21779562
172. Han XZ, Shen T, Lou HX. Dietary polyphenols and their biological significance. Int J Mol Sci (2007) 8(9):950–88.10.3390/i8090950
173. Wiczkowski W, Romaszko E, Piskula MK. Bioavailability of cyanidin glycosides from natural chokeberry (Aronia melanocarpa) juice with dietary-relevant dose of anthocyanins in humans. J Agric Food Chem (2010) 58(23):12130–6.10.1021/jf102979z21067240
174. McDougall GJ, Fyffe S, Dobson P, Stewart D. Anthocyanins from red wine – their stability under simulated gastrointestinal digestion. Phytochemistry (2005) 66(21):2540–8.10.1016/j.phytochem.2005.09.00316242736
175. McDougall GJ, Dobson P, Smith P, Blake A, Stewart D. Assessing potential bioavailability of raspberry anthocyanins using an in vitro digestion system. J Agric Food Chem (2005) 53(15):5896–904.10.1021/jf050131p16028971
176. Yang M, Koo SI, Song WO, Chun OK. Food matrix affecting anthocyanin bioavailability: review. Curr Med Chem (2011) 18(2):291–300.10.2174/09298671179408838021110799
177. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr (2000) 130(8S Suppl):2073S–85S.10917926
178. Yang HL, Chen SC, Lin KY, Wang MT, Chen YC, Huang HC, et al. Antioxidant activities of aqueous leaf extracts of Toona sinensis on free radical-induced endothelial cell damage. J Ethnopharmacol (2011) 137(1):669–80.10.1016/j.jep.2011.06.01721718778
179. Stoner GD, Sardo C, Apseloff G, Mullet D, Wargo W, Pound V, et al. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J Clin Pharmacol (2005) 45(10):1153–64.10.1177/009127000527963616172180
180. Faria A, Fernandes I, Norberto S, Mateus N, Calhau C. Interplay between anthocyanins and gut microbiota. J Agric Food Chem (2014) 62(29):6898–902.10.1021/jf501808a24915058
181. Banini AE, Boyd LC, Allen JC, Allen HG, Sauls DL. Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects. Nutrition (2006) 22(11–12):1137–45.10.1016/j.nut.2006.08.01217030113
182. Khanizadeh S, Tsao R, Rekika D, Yang R, DeEll J. Phenolic composition and antioxidant activity of selected apple genotypes. J Food Agric Environ (2007) 5(1):61–6.
183. Chiou A, Salta FN, Kalogeropoulos N, Mylona A, Ntalla I, Andrikopoulos NK. Retention and distribution of polyphenols after pan-frying of French fries in oil enriched with olive leaf extract. J Food Sci (2007) 72(8):S574–84.10.1111/j.1750-3841.2007.00493.x17995623
184. Haenen GR, Paquay JB, Korthouwer RE, Bast A. Peroxynitrite scavenging by flavonoids. Biochem Biophys Res Commun (1997) 236(3):591–3.10.1006/bbrc.1997.7016
185. Hogg N, Darleyusmar V, Graham A, Moncada S, Kalyanaraman B. The modification of low-density-lipoprotein (Ldl) by peroxynitrite and systems generating nitric-oxide (No) and superoxide. Free Radic Biol Med (1993) 15(5):495.10.1016/0891-5849(93)90277-2
186. Yamakoshi J, Kataoka S, Koga T, Ariga T. Proanthocyanidin-rich extract from grape seeds attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Atherosclerosis (1999) 142(1):139–49.10.1016/S0021-9150(98)00230-59920515
187. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr (2001) 131(8):2082–9.11481398
188. Andriambeloson E, Magnier C, Haan-Archipoff G, Lobstein A, Anton R, Beretz A, et al. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. J Nutr (1998) 128(12): 2324–33.9868177
189. Wallerath T, Li H, Godtel-Ambrust U, Schwarz PM, Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide (2005) 12(2):97–104.10.1016/j.niox.2004.12.00415740983
190. de Nigris F, Williams-Ignarro S, Lerman LO, Crimi E, Botti C, Mansueto G, et al. Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc Natl Acad Sci U S A (2005) 102(13):4896–901.10.1073/pnas.050099810215781875
191. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation (1999) 100(10):1050–5.10.1161/01.CIR.100.10.105010477529
192. Polagruto JA, Wang-Polagruto JF, Braun MM, Lee L, Kwik-Uribe C, Keen CL. Cocoa flavanol-enriched snack bars containing phytosterols effectively lower total and low-density lipoprotein cholesterol levels. J Am Diet Assoc (2006) 106(11):1804–13.10.1016/j.jada.2006.08.01217081832
193. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol (2003) 23(4):622–9.10.1161/01.ATV.0000062884.69432.A012615669
194. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans (2007) 35(Pt 5):1156–60.10.1042/BST035115617956300
195. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res (2005) 49(5):405–30.10.1002/mnfr.20050002215832402
196. Karatzi K, Papamichael C, Karatzis E, Papaioannou TG, Voidonikola PT, Lekakis J, et al. Acute smoking induces endothelial dysfunction in healthy smokers. Is this reversible by red wine’s antioxidant constituents? J Am Coll Nutr (2007) 26(1):10–5.10.1080/07315724.2007.1071958017353578
197. Martin S, Giannone G, Andriantsitohaina R, Martinez MC. Delphinidin, an active compound of red wine, inhibits endothelial cell apoptosis via nitric oxide pathway and regulation of calcium homeostasis. Br J Pharmacol (2003) 139(6):1095–102.10.1038/sj.bjp.070534712871827
198. Rechner AR, Kroner C. Anthocyanins and colonic metabolites of dietary polyphenols inhibit platelet function. Thromb Res (2005) 116(4):327–34.10.1016/j.thromres.2005.01.00216038718
199. Freedman JE, Parker C, III Li L, Perlman JA, Frei B, Ivanov V, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation (2001) 103(23):2792–8.10.1161/01.CIR.103.23.279211401934
200. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation (1995) 91(4):1182–8.10.1161/01.CIR.91.4.11827850957
201. Duarte J, Galisteo M, Ocete MA, Perez-Vizcaino F, Zarzuelo A, Tamargo J. Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. Mol Cell Biochem (2001) 221(1–2):155–60.10.1023/A:101095692858411506179
202. Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez-Vizcaino F, Zarzuelo A, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol (2001) 133(1):117–24.10.1038/sj.bjp.070406411325801
203. Han JJ, Hao J, Kim CH, Hong JS, Ahn HY, Lee YS. Quercetin prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Med Sci (2009) 71(6):737–43.10.1292/jvms.71.73719578281
204. Jalili T, Carlstrom J, Kim S, Freeman D, Jin H, Wu TC, et al. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol (2006) 47(4):531–41.10.1097/01.fjc.0000211746.78454.5016680066
205. Pereira Braga C, Momentti AC, Barbosa Peixoto F, de Fatima Ferreira Baptista R, dos Santos FA, Fava FH, et al. Influence of treatment with quercetin on lipid parameters and oxidative stress of pregnant diabetic rats. Can J Physiol Pharmacol (2013) 91(2):171–7.10.1139/cjpp-2012-017323458202
206. Heeba GH, Mahmoud ME, Hanafy AA. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-alpha. Toxicol Ind Health (2014) 30(6):551–60.10.1177/074823371246244423024111
207. Choi EJ, Kim T, Kim GH. Quercetin acts as an antioxidant and downregulates CYP1A1 and CYP1B1 against DMBA-induced oxidative stress in mice. Oncol Rep (2012) 28(1):291–6.10.3892/or.2012.175322469840
208. Luangaram S, Kukongviriyapan U, Pakdeechote P, Kukongviriyapan V, Pannangpetch P. Protective effects of quercetin against phenylhydrazine-induced vascular dysfunction and oxidative stress in rats. Food Chem Toxicol (2007) 45(3):448–55.10.1016/j.fct.2006.09.00817084956
209. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet (1993) 342(8878):1007–11.10.1016/0140-6736(93)92876-U8105262
210. Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet (1997) 349(9053):699.10.1016/S0140-6736(05)60135-3
211. Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam study. Am J Clin Nutr (2002) 75(5):880–6.11976162
212. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr (2008) 88(1):38–50.18614722
213. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr (2009) 102(7):1065–74.10.1017/S000711450935912719402938
214. Mursu J, Nurmi T, Tuomainen TP, Ruusunen A, Salonen JT, Voutilainen S. The intake of flavonoids and carotid atherosclerosis: the Kuopio ischaemic heart disease risk factor study. Br J Nutr (2007) 98(4):814–8.10.1017/S000711450774441017466095
215. Djousse L, Hopkins PN, Arnett DK, Pankow JS, Borecki I, North KE, et al. Chocolate consumption is inversely associated with calcified atherosclerotic plaque in the coronary arteries: the NHLBI family heart study. Clin Nutr (2011) 30(1):38–43.10.1016/j.clnu.2010.06.01120655129
216. Curtis PJ, Potter J, Kroon PA, Wilson P, Dhatariya K, Sampson M, et al. Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a double-blind randomized controlled trial. Am J Clin Nutr (2013) 97(5):936–42.10.3945/ajcn.112.04374523553151
217. Gronbaek M, Deis A, Sorensen TI, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits. BMJ (1995) 310(6988):1165–9.10.1136/bmj.310.6988.11657767150
218. Semba RD, Ferrucci L, Bartali B, Urpi-Sarda M, Zamora-Ros R, Sun K, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med (2014) 174(7):1077–84.10.1001/jamainternmed.2014.158224819981
219. Schrieks IC, van den Berg R, Sierksma A, Beulens JW, Vaes WH, Hendriks HF. Effect of red wine consumption on biomarkers of oxidative stress. Alcohol Alcohol (2013) 48(2):153–9.10.1093/alcalc/ags08622859618
220. Tozzi Ciancarelli MG, Di Massimo C, De Amicis D, Ciancarelli I, Carolei A. Moderate consumption of red wine and human platelet responsiveness. Thromb Res (2011) 128(2):124–9.10.1016/j.thromres.2011.03.01521489606
221. Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, et al. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. Nutr J (2013) 12(1):147.10.1186/1475-2891-12-14724228901
222. Chiva-Blanch G, Urpi-Sarda M, Ros E, Valderas-Martinez P, Casas R, Arranz S, et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin Nutr (2013) 32(2):200–6.10.1016/j.clnu.2012.08.02222999066
223. Chiva-Blanch G, Urpi-Sarda M, Ros E, Arranz S, Valderas-Martinez P, Casas R, et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication. Circ Res (2012) 111(8):1065–8.10.1161/CIRCRESAHA.112.27563622955728
224. Di Renzo L, Carraro A, Valente R, Iacopino L, Colica C, De Lorenzo A. Intake of red wine in different meals modulates oxidized LDL level, oxidative and inflammatory gene expression in healthy people: a randomized crossover trial. Oxid Med Cell Longev (2014) 2014:681318.10.1155/2014/68131824876915
225. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, et al. Selenium in human health and disease. Antioxid Redox Signal (2011) 14(7):1337–83.10.1089/ars.2010.3275
226. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr (2006) 84(4): 762–73.17023702
227. Rees K, Hartley L, Day C, Flowers N, Clarke A, Stranges S. Selenium supplementation for the primary prevention of cardiovascular disease (review). Cochrane Database Syst Rev (2013) 1:CD009671.10.1002/14651858.CD009825.pub2
228. Beck MA, Esworthy RS, Ho YS, Chu FF. Glutathione peroxidase protects mice from viral-induced myocarditis. FASEB J (1998) 12(12):1143–9.9737717
229. Lei C, Niu X, Wei J, Zhu J, Zhu Y. Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy. Clin Chim Acta (2009) 399(1–2):102–8.10.1016/j.cca.2008.09.02518940188
230. Ge K, Yang G. The epidemiology of selenium deficiency in the etiological study of endemic diseases in China. Am J Clin Nutr (1993) 57(2 Suppl):259S–63S.8427200
231. Alfthan G, Xu GL, Tan WH, Aro A, Wu J, Yang YX, et al. Selenium supplementation of children in a selenium-deficient area in China – blood selenium levels and glutathione peroxidase activities. Biol Trace Elem Res (2000) 73(2):113–25.10.1385/BTER:73:2:11311049204
232. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther (2014) 141(2):150–9.10.1016/j.pharmthera.2013.09.00624080471
233. Meister A, Anderson ME. Glutathione. Annu Rev Biochem (1983) 52:711–60.10.1146/annurev.bi.52.070183.003431
234. Prescott LF, Ballantyne A, Park J, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet (1977) 2(8035):432–4.10.1016/S0140-6736(77)90612-270646
235. Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care (2008) 31(5):940–4.10.2337/dc07-225118268065
236. Treweeke AT, Winterburn TJ, Mackenzie I, Barrett F, Barr C, Rushworth GF, et al. N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia (2012) 55(11):2920–8.10.1007/s00125-012-2685-z22935960
237. Mazzanti L, Mutus B. Diabetes-induced alterations in platelet metabolism. Clin Biochem (1997) 30(7):509–15.10.1016/S0009-9120(97)00094-5
238. Gibson KR, Winterburn TJ, Barrett F, Sharma S, MacRury SM, Megson IL. Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes. Cardiovasc Diabetol (2011) 10:43.10.1186/1475-2840-10-4321600014
239. Tamariz L, Harzand A, Palacio A, NVerna S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail (2011) 17:25–30.10.1111/j.1751-7133.2011.00200.x21272224
240. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol (2006) 290:H837–43.10.1152/ajpheart.00831.200516183726
241. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine post-ischemic cardiomyopathy. Circ Res (2004) 95:1005–11.10.1161/01.RES.0000148635.73331.c515499028
242. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 104:2407–11.10.1161/hc4501.09892811705816
243. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphosphate energy delivery in failing human hearts. J Am Coll Cardiol (2012) 59:802–8.10.1016/j.jacc.2011.10.89522361399
244. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al. Effect of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation (2015) 131:1763–71.10.1161/CIRCULATIONAHA.114.01453625986447
245. Hare JM, Mangal B, Brown J, Fisher CJ, Freudennberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol (2008) 51:2301–9.10.1016/j.jacc.2008.01.06818549913
246. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart (2005) 91:749–53.10.1136/hrt.2004.04047715894768
247. Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Nevarro M, et al. Xanthine oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant (2011) 30:408–13.10.1016/j.healun.2010.10.00321145258
248. Nasr G, Maurice C. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res (2010) 1:191–5.10.4103/0975-3583.7426221264183
249. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Perez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients. La plat study. J Card Fail (2006) 12:491–8.10.1016/j.cardfail.2006.05.00516952781
250. Tamariz L, Hare JM. Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation (2015) 131:1741–4.10.1161/CIRCULATIONAHA.115.016379
251. Okuda N, Miura K, Okayama A, Okamura T, Abbott RD, Nishi N, et al. Fruit and vegetable intake and mortality from cardiovascular disease in Japan: a 24-year follow-up of the NIPPON DATA80 Study. Eur J Clin Nutr (2015) 69(4):482–8.10.1038/ejcn.2014.27625585600
252. Li NY, Li K, Qi Z, Demonty I, Gordon M, Francis L, et al. Plant sterol-enriched milk tea decreases blood cholesterol concentrations in Chinese adults: a randomised controlled trial. Br J Nutr (2007) 98(5):978–83.10.1017/S000711450775430217617940